Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention
Joint Authors
Tse, Gary
Li, Guangping
Shao, Shuai
Liu, Tong
Shi, Zhaozhao
Wang, Xinghua
Ni, Yanping
Liu, Hongmei
Source
Cardiology Research and Practice
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-02
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Objectives.
Trimetazidine is an anti-ischemic medication licensed for the treatment of angina pectoris.
However, the molecular mechanisms underlying its action remain incompletely elucidated.
In this study, therefore, we examined the potential beneficial effects of trimetazidine on myocardial injury and endothelial dysfunction in patients with unstable angina in the perioperative period of percutaneous coronary intervention (PCI).
Methods.
A total of 97 patients with unstable angina were randomly divided into trimetazidine (n = 48) and control (n = 49) groups.
All subjects received standard medical therapy.
The trimetazidine group additionally received 20 mg trimetazidine three times daily 24 hours before and after PCI.
Serum levels of creatine kinase-muscle/brain (CK-MB), cardiac troponin I (cTnI), heart-type fatty acid-binding protein (h-FABP), von Willebrand factor (vWF), and nitric oxide (NO) were measured before and the morning following PCI.
Results.
In the control group, levels of CK-MB, cTnI, and vWF were significantly elevated (P<0.05) and NO level was decreased after PCI (P<0.05).
By contrast, no significant changes in the levels of these proteins were observed in the trimetazidine group after PCI (P>0.05).
Moreover, h-FABP levels were not significantly altered after PCI whether in the control or in the trimetazidine group (P>0.05).
Finally, a time-dependent increase in the levels of h-FABP from 0 to 6 hours after PCI, followed by a progressive decline, was observed (P<0.05).
Conclusions.
PCI induces endothelial dysfunction and myocardial damage in patients with unstable angina.
Trimetazidine therapy in the perioperative period can reduce this damage.
American Psychological Association (APA)
Shao, Shuai& Shi, Zhaozhao& Tse, Gary& Wang, Xinghua& Ni, Yanping& Liu, Hongmei…[et al.]. 2019. Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention. Cardiology Research and Practice،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1145957
Modern Language Association (MLA)
Shao, Shuai…[et al.]. Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention. Cardiology Research and Practice No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1145957
American Medical Association (AMA)
Shao, Shuai& Shi, Zhaozhao& Tse, Gary& Wang, Xinghua& Ni, Yanping& Liu, Hongmei…[et al.]. Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention. Cardiology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1145957
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1145957